Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Anagrelide
Drug ID BADD_D00139
Description Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274]
Indications and Usage For the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
Marketing Status Prescription; Discontinued
ATC Code L01XX35
DrugBank ID DB00261
KEGG ID D07455
MeSH ID C021139
PubChem ID 135409400
TTD Drug ID D0D1HW
NDC Product Code 13668-453; 13668-462
Synonyms anagrelide | Agrylin | BL 4162A | Agrelin | anagrelide hydrochloride | imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride | 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one hydrochloride
Chemical Information
Molecular Formula C10H7Cl2N3O
CAS Registry Number 68475-42-3
SMILES C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Chronic myeloid leukaemiaTyrosine-protein kinase ABL1P00519T6350511841409; 11273186; 9516377; 15510207
ThalassaemiaTyrosine-protein kinase ABL1P00519T6350511841409; 11273186; 9516377; 15510207
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.002--
Acute myocardial infarction02.02.02.001; 24.04.04.0010.000533%Not Available
Alopecia23.02.02.001--
Alveolitis allergic22.01.01.002; 10.01.03.008--Not Available
Amblyopia06.02.01.001--Not Available
Amnesia19.20.01.001; 17.03.02.001--
Anaemia01.03.02.0010.000533%
Angina pectoris24.04.04.002; 02.02.02.002--
Aphthous ulcer07.05.06.002--Not Available
Arrhythmia02.03.02.001--Not Available
Arrhythmia supraventricular02.03.03.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atrial fibrillation02.03.03.002--
Atrioventricular block complete02.03.01.003--
Back pain15.03.04.005--
Blood creatinine increased13.13.01.004--
Blood pressure increased13.14.03.0050.000533%Not Available
Body temperature increased13.15.01.001--Not Available
Bone pain15.02.01.001--
Bronchitis22.07.01.001; 11.01.09.001--
Cardiac arrest02.03.04.0010.000139%
Cardiac failure02.05.01.0010.000139%
Cardiac failure congestive02.05.01.002--Not Available
Cardiomegaly02.04.02.001--Not Available
Cardiomyopathy02.04.01.0010.000533%Not Available
Cardiovascular disorder24.03.02.009; 02.01.01.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages